--- title: "Neogenomics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 186.67 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/284449318.md" datetime: "2026-04-28T21:03:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284449318.md) - [en](https://longbridge.com/en/news/284449318.md) - [zh-HK](https://longbridge.com/zh-HK/news/284449318.md) --- # Neogenomics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 186.67 M Revenue: As of FY2026 Q1, the actual value is USD 186.67 M, beating the estimate of USD 184.48 M. EPS: As of FY2026 Q1, the actual value is USD -0.13, beating the estimate of USD -0.1588. EBIT: As of FY2026 Q1, the actual value is USD -18.92 M. #### First Quarter 2026 Financial Highlights **Total Revenue**NeoGenomics, Inc. reported a consolidated revenue of $187 million for the first quarter of 2026, an 11% increase year-over-year compared to $168.035 million in the first quarter of 2025. Clinical revenue grew by 14%, including NGS growth of 26%. **Net Loss**The net loss for the first quarter of 2026 was - $17.106 million, a 34% decrease from the net loss of - $25.923 million in the first quarter of 2025. **Adjusted EBITDA**Adjusted EBITDA for the first quarter of 2026 was $9.004 million, a 27% increase compared to $7.070 million in the first quarter of 2025. **Gross Profit**Consolidated gross profit for the first quarter of 2026 was $80.864 million, a 10% increase from $73.246 million in the first quarter of 2025. **Gross Profit Margin**The GAAP consolidated gross profit margin was 43.3% for Q1 2026, compared to 43.6% for Q1 2025. The Adjusted Gross Profit Margin was 46.0% for Q1 2026, down from 46.8% for Q1 2025. **Operating Expenses**Total operating expenses for the first quarter of 2026 were $99.105 million, a 2% decrease from $101.071 million in the first quarter of 2025. This includes General and administrative expenses of $65.741 million, Research and development expenses of $9.534 million, and Sales and marketing expenses of $23.830 million for Q1 2026. **Adjusted Net Income/(Loss)**Adjusted net income was $1.371 million for Q1 2026, compared to an Adjusted net loss of - $0.459 million in Q1 2025. **Cash and Cash Equivalents**Cash and cash equivalents and marketable securities totaled $146 million at quarter end. Cash and cash equivalents were $146.143 million as of March 31, 2026, down from $159.618 million as of December 31, 2025. **Operating Cash Flow**Net cash used in operating activities was - $8.137 million for the three months ended March 31, 2026, an improvement from - $25.327 million for the same period in 2025. **Investing Activities**Net cash used in investing activities was - $5.000 million for the three months ended March 31, 2026, compared to $3.560 million provided by investing activities in the prior year period. **Financing Activities**Net cash used in financing activities was - $0.338 million for the three months ended March 31, 2026, compared to $0.949 million provided by financing activities in the prior year period. #### Operational Metrics **Clinical Tests Performed**The number of clinical tests performed, including Pathline, increased by 6.0% to 345,679 in Q1 2026 from 326,163 in Q1 2025. Excluding Pathline, the number of tests performed increased by 2.8% to 335,155. **Average Revenue Per Clinical Test**Average revenue per clinical test increased by 7.8% to $495 in Q1 2026 from $459 in Q1 2025. Excluding Pathline tests, average revenue per clinical test increased by 9.2% to $501. **Product Launches and Coverage**NeoGenomics, Inc. launched RaDaR® ST, a circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD), which is estimated to address a $20 billion market growing at 30% annually. The company also announced a favorable MolDX coverage decision for PanTracer™ LBx and introduced PanTracer Pro. #### Outlook / Guidance NeoGenomics, Inc. revised its full-year 2026 revenue guidance to a range of $797 million to $803 million, representing a 10% year-over-year increase from 2025. The company expects a net loss between - $63 million and - $50 million, and Adjusted EBITDA guidance is maintained at $55 million to $57 million. ### Related Stocks - [NEO.US](https://longbridge.com/en/quote/NEO.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md) - [Royce Small-Cap Trust (NYSE: RVT) as of Apr 30, 2026 | RVT Stock News](https://longbridge.com/en/news/287103750.md)